Sorafenib Plus Intensive Chemotherapy Improves Outcomes in FLT3-Mutated Acute Myeloid Leukemia
Median overall survival was 42 months in patients who received sorafenib and 13 months in patients who received chemotherapy alone.
Lauren Dembeck, PhD
Contributing Writer https://www.cancertherapyadvisor.com
Lauren Dembeck is a freelance science and medical writer and a contributing author for the Haymarket Medical Network. She holds a BS in biology and a BA in foreign languages from West Virginia University and a PhD in genetics from North Carolina State University. Prior to freelance writing, Lauren was a postdoctoral researcher at the Okinawa Institute of Science and Technology in Japan, where she studied developmental neurobiology. You can find more of her writing at https://laurendembeck.com/
